Székely E, Vereckei A, Almási A, Rapavi E, Tasnádi Gy, Várnai K, Pallai Zs, Lugasi A, Blázovics Anna
Central Hospital of the Hungarian State Railways-Budapest, Hungarian Porphyria Center, Podmaniczky Street 111, H-1062 Budapest, Hungary.
Clin Hemorheol Microcirc. 2007;36(1):13-23.
Conflicting results were reported about the efficacy of vitamin E (E) treatment in porphyria cutanea tarda (PCT). We conducted a study in PCT patients to investigate whether E treatment has any additional beneficial effects compared with phlebotomy (P) treatment alone on rheological and oxidative stress parameters.
Twenty three patients with sporadic PCT in clinical remission and 10 healthy control patients were studied. All patients were treated with P prior to the study until clinical remission was achieved. Baseline routine laboratory [blood glucose, serum lipids, C-reactive protein (CRP), iron metabolism indices, liver function tests], oxidative stress [serum thiobarbituric acid reactive substances (TBARS), plasma H-donor activity, plasma free SH-groups, erythrocyte glutathion peroxidase activity] and rheological parameters (whole blood and plasma viscosity, cell transit time, clogging rate) were measured in both groups. Then all PCT patients received E (tocopherol acetate) 200 mg/day for 8 weeks and at the end of treatment measurements identical to those performed at baseline were repeated.
Increased urine uroporphyrin, serum CRP, TBARS concentrations, whole blood and plasma viscosity and decreased plasma H-donor activity, free SH-group level, erythrocyte glutathione peroxidase activity were detected in PCT patients treated with P alone compared with control group consistent with residual oxidative stress in PCT patients. E treatment decreased urine uroporphyrin and serum TBARS concentrations; increased plasma H-donor activity and did not influence whole blood and plasma viscosity compared with P treatment alone.
E treatment reduced the residual oxidative stress and did not influence increased plasma and whole blood viscosity present in PCT patients receiving P treatment prior to clinical remission.
关于维生素E(E)治疗迟发性皮肤卟啉病(PCT)的疗效,报告结果相互矛盾。我们对PCT患者进行了一项研究,以调查与单纯放血疗法(P)相比,E治疗在流变学和氧化应激参数方面是否具有任何额外的有益效果。
对23例临床缓解期的散发性PCT患者和10例健康对照患者进行了研究。所有患者在研究前均接受P治疗,直至达到临床缓解。两组均测量了基线常规实验室指标[血糖、血脂、C反应蛋白(CRP)、铁代谢指标、肝功能检查]、氧化应激指标[血清硫代巴比妥酸反应性物质(TBARS)、血浆氢供体活性、血浆游离巯基、红细胞谷胱甘肽过氧化物酶活性]和流变学参数(全血和血浆粘度、细胞通过时间、阻塞率)。然后,所有PCT患者接受200mg/天的E(醋酸生育酚)治疗,持续8周,治疗结束时重复进行与基线相同的测量。
与对照组相比,单纯接受P治疗的PCT患者尿卟啉、血清CRP、TBARS浓度升高,全血和血浆粘度增加,血浆氢供体活性、游离巯基水平、红细胞谷胱甘肽过氧化物酶活性降低,这与PCT患者残留的氧化应激一致。与单纯P治疗相比,E治疗降低了尿卟啉和血清TBARS浓度;增加了血浆氢供体活性,且未影响全血和血浆粘度。
E治疗降低了残留的氧化应激,且未影响临床缓解前接受P治疗的PCT患者中升高的血浆和全血粘度。